Back to top Open menu arrow
Purchase PDF

Save Save

Cite Cite

Reprints
Sections
METHODS RESULTS DISCUSSION CONCLUSIONS Article Information Clinical Points
Primary Care Companion for CNS Disorders Primary Care Companion for CNS Disorders

The Primary
Care Companionfor CNS Disorders
Access icon

Systematic Review January 16, 2024

Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review

; ; ; ;

Prim Care Companion CNS Disord 2024;26(1):23r03581

ABSTRACT

Objective: To investigate the relationship between psychedelic microdosing and its effects on mental health, aiming to understand if microdosing can improve mental well-being.

Data Sources: PubMed and Scopus were searched on December 25, 2022, using search terms related to psychedelics, microdosing, and mental health. The inclusion criteria focused on studies published between January 1, 2012, and November 30, 2022. There were no language restrictions for the initial search; however, for the study selection, only articles in English were considered.

Study Selection: A total of 45 articles were initially identified. After removing duplicates, 27 unique articles were screened based on their titles and abstracts, resulting in 19 articles included in the final review. The studies were selected based on their relevance to the relationship between mental health and psychedelic microdosing.

Data Extraction: The extracted data from the selected studies included sample sizes, demographics, survey designs, and qualitative and quantitative analyses related to the outcomes of individuals with mental health issues who also engaged in psychedelic microdosing. The QualSyst Quality Assessment Checklist was used to assess the methodological rigor and quality of each study. The data extraction process involved systematically reviewing each article and summarizing key findings related to the impact of microdosing on mental health.

Results: The review revealed that microdosing psychedelics, such as lysergic acid diethylamide and psilocybin, showed potential benefits on mental health. Users reported positive effects, including improved mood, increased focus, and better daily function. However, there were also challenges reported, such as physiologic discomfort and increased anxiety. Some studies observed that positive expectations about microdosing led to positive outcomes. The studies varied in design, with some being observational, others placebo-controlled, and some relying on self-reported data.

Conclusions: There is a growing body of evidence suggesting a positive correlation between psychedelic microdosing and improved mental well-being. However, due to the limited number of controlled studies and the small sample sizes in some of the studies, the causal relationship between microdosing and mental health improvement remains uncertain. The review calls for further research with double-blind experiments, control groups, and larger sample sizes that represent the general population to better understand the potential benefits and risks of psychedelic microdosing on mental health.

Prim Care Companion CNS Disord 2024;26(1):23r03581

Author affiliations are listed at the end of this article

  1. Hasin D. New Study Estimates Over 5.5 Million US Adults Use Hallucinogens. 2022. Accessed December 25, 2022.https://www.publichealth.columbia.edu/news/new-study-estimates-over-5-5-million-u-s-adults-use-hallucinogens
  2. Lowe H, Toyang N, Steele B, et al. The therapeutic potential of psilocybin. Molecules. 2021;26(10):2948. PubMed CrossRef
  3. Martin DA, Nichols CD. The effects of hallucinogens on gene expression. Curr Top Behav Neurosci. 2018;36:137–158. PubMed CrossRef
  4. Hallucinogens and Dissociative Drugs. Research report brochure. United States Department of Health and Human Services, National Institute of Health. Accessed December 25, 2022. https://nida.nih.gov/sites/default/files/rrhalluc.pdf
  5. Polito V, Liknaitzky P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706. PubMed CrossRef
  6. Johnstad PG. Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordisk Alkohol Nark. 2018;35(1):39–51. PubMed CrossRef
  7. Rootman JM, Kryskow P, Harvey K, et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Sci Rep. 2021;11(1):22479. PubMed CrossRef
  8. Yanakieva S, Polychroni N, Family N, et al. The effects of microdose LSD on time perception: a randomized, double-blind, placebo-controlled trial. (published correction appears in Psychopharmacology (Berl) Psychopharmacology (Berl). 2019;236(4):1159–1170. PubMed CrossRef
  9. Forsyth B, Machado L, Jowett T, et al. Effects of low dose ibogaine on subjective mood state and psychological performance. J Ethnopharmacol. 2016;189:10–13. PubMed CrossRef
  10. Goutarel R, Golnhoffer N, Siddens R. Pharmacodynamics and therapeutic applications of iboga and ibogaine. (translated from French by Gladstone WJ). Psychedelic Monogr Essays. 1993;6:70–111.
  11. Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans, I: neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994;51(2):85–97. PubMed CrossRef
  12. Shulgin AT. DMT & TMA-2. J Psychedelic Drugs. 1976;8(2):167–169. CrossRef
  13. Madsen MK, Fisher PM, Burmester D, et al. Correction: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1336–1337. PubMed CrossRef
  14. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218(4):649–665. PubMed CrossRef
  15. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49–69. PubMed CrossRef
  16. Hasler F, Bourquin D, Brenneisen R, et al. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 1997;72(3):175–184. PubMed CrossRef
  17. Turton S, Nutt DJ, Carhart-Harris RL. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment. Curr Drug Abuse Rev. 2014;7(2):117–127. PubMed CrossRef
  18. Moher D, Shamseer L, Clarke M, et al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PubMed CrossRef
  19. Anderson T, Petranker R, Christopher A, et al. Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J. 2019;16(1):43. PubMed CrossRef
  20. Anderson T, Petranker R, Rosenbaum D, et al. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology (Berl). 2019;236(2):731–740. PubMed CrossRef
  21. Beaton B, Copes H, Webb M, et al. Accounting for microdosing classic psychedelics. J Drug Issues. 2020;50(1):3–14. CrossRef
  22. Bright S, Gringart E, Blatchford E, et al. A quantitative exploration of the relationships between regular yoga practice, microdosing psychedelics, well-being and personality variables. Aust J Psychol. 2021;73(2):134–143. CrossRef
  23. Cameron LP, Nazarian A, Olson DE. Psychedelic microdosing: prevalence and subjective effects. J Psychoactive Drugs. 2020;52(2):113–122. PubMed CrossRef
  24. Hutten NRPW, Mason NL, Dolder PC, et al. Motives and side-effects of microdosing with psychedelics among users. Int J Neuropsychopharmacol. 2019;22(7):426–434. PubMed CrossRef
  25. Hutten NRPW, Mason NL, Dolder PC, et al. Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psychiatry. 2019;10:672. PubMed CrossRef
  26. Kaertner LS, Steinborn MB, Kettner H, et al. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep. 2021;11(1):1941. PubMed CrossRef
  27. Lea T, Amada N, Jungaberle H. Psychedelic microdosing: a subreddit analysis. J Psychoactive Drugs. 2020;52(2):101–112. PubMed CrossRef
  28. Lea T, Amada N, Jungaberle H, et al. Microdosing psychedelics: motivations, subjective effects and harm reduction. Int J Drug Policy. 2020;75:102600. PubMed CrossRef
  29. Lea T, Amada N, Jungaberle H, et al. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacology (Berl). 2020;237(5):1521–1532. PubMed CrossRef
  30. Petranker R, Anderson T, Maier LJ, et al. Microdosing psychedelics: subjective benefits and challenges, substance testing behavior, and the relevance of intention. (published correction appears in J Psychopharmacol). J Psychopharmacol. 2022;36(1):85–96. PubMed CrossRef
  31. Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One. 2019;14(2):e0211023. PubMed CrossRef
  32. Prochazkova L, Lippelt DP, Colzato LS, et al. Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. Psychopharmacology (Berl). 2018;235(12):3401–3413. PubMed CrossRef
  33. Rosenbaum D, Weissman C, Anderson T, et al. Microdosing psychedelics: demographics, practices, and psychiatric comorbidities. J Psychopharmacol. 2020;34(6):612–622. PubMed CrossRef
  34. Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021;10:e62878. PubMed CrossRef
  35. Webb M, Copes H, Hendricks PS. Narrative identity, rationality, and microdosing classic psychedelics. Int J Drug Policy. 2019;70:33–39. PubMed CrossRef
  36. Higgins JPT, Thomas J, Chandler J, et al Cochrane Handbook for Systematic Reviews of Interventions, Version 6.4. Updated August 2023. Cochrane, 2023. Accessed December 25, 2022. www.training.cochrane.org/handbook
  37. Schünemann H, Brożek J, Guyatt G, et al, eds. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group; 2013.
  38. Kmet LM, Cook LS, Lee RC. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. 2004. Alberta Heritage Foundation for Medical Research (AHFMR). Accessed December 25, 2022. https://www.ihe.ca/advanced-search/standard-quality-assessment-criteria-for-evaluating-primary-research-papers-from-a-variety-of-fields
  39. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. PubMed CrossRef

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

Save Save

Cite Cite

Vol 27 • 2025 • Number 3

Read the Current Issue

Original Research

Conflict Mediation by CBT

Systematic Review

Psychiatric Adverse Effects of Hydroxychloroquine

Review Article

Efficacy of GLP-1 Agonists in Mental Disorders

Rounds in the General Hospital

Time-Limited Teaching of Psychiatry to Medical Students

Rounds in the General Hospital

Multimodal Approaches to Pain Management

Rounds in the General Hospital

Sequelae of Adverse Childhood Experiences
View current Issue

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe